New York, United States:
Sales of the Covid-19 vaccine created by Pfizer and BioNTech could attain up to $15 billion in 2021 and go larger if Pfizer indicators extra provide contracts, Pfizer mentioned Tuesday.
The projections came as Pfizer projected complete-year 2021 sales of involving $59.4 billion and $61.4 billion, which means that about one-fourth of estimated total sales will come from the Covid-19 vaccine.
The forecast reflects “a continued recovery in macroeconomic and healthcare activity throughout 2021 as more of the population becomes vaccinated against Covid-19,” Pfizer mentioned.
“These assumptions are guided by the trajectory of current infection rates in many parts of the world and the expected timeline for broad access to effective vaccines.”
Pfizer reported fourth-quarter net revenue of $594 million, compared with a loss of $337 million in the year-ago period.
For all of 2020, Pfizer reported earnings of $9.6 billion, down 41.4 % from 2019, with revenues up two % to $41.9 billion.
Pfizer’s fourth-quarter revenues integrated $154 million in sales of the Covid-19 vaccine.
The vaccine started winning approval from authorities late final year. Pfizer mentioned it expects it could potentially provide up to 2 billion doses in 2021 based on various variables, like adding more suppliers and contract producers.
Shares of Pfizer rose .5 % to $35.94 in pre-industry trading.